Literature DB >> 2971496

Inhibition of polymorphonuclear leukocyte chemotaxis by the mucoid exopolysaccharide of Pseudomonas aeruginosa.

H G Stiver1, K Zachidniak, D P Speert.   

Abstract

We tested the effect on human polymorphonuclear leukocyte (PMN) chemotaxis of the mucoid exopolysaccharide (MEP) elaborated by Pseudomonas aeruginosa strain P1M recovered from the sputum of a patient with cystic fibrosis (CF). A dose-related inhibition of chemotaxis under agarose was observed when mucoid exopolysaccharide at concentrations of 0.5 to 5.0 mg/ml was incorporated into the agarose. Similar inhibition was observed with the closely related polysaccharide alginic acid, but not with the neutral polymer Ficoll. The exopolysaccharide did not bind or inactivate the chemoattractant substance, nor was it toxic to PMN's. Digestion with alginase did significantly abrogate the inhibitory effect of alginic acid, but not of MEP. There was no difference in chemotaxis in the presence of the exopolysaccharide preincubated with heat-inactivated pooled antisera from CF patients chronically colonized with mucoid P. aeruginosa compared to MEP alone, or MEP preincubated with heat-inactivated pooled normal human sera. Inhibition of chemotaxis may represent yet another pathogenetic property of P. aeruginosa mucoid exopolysaccharide.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2971496

Source DB:  PubMed          Journal:  Clin Invest Med        ISSN: 0147-958X            Impact factor:   0.825


  15 in total

Review 1.  Biofilm consortia on biomedical and biological surfaces: delivery and targeting strategies.

Authors:  V Sihorkar; S P Vyas
Journal:  Pharm Res       Date:  2001-09       Impact factor: 4.200

Review 2.  Establishment of aging biofilms: possible mechanism of bacterial resistance to antimicrobial therapy.

Authors:  H Anwar; J L Strap; J W Costerton
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

3.  Global genomic analysis of AlgU (sigma(E))-dependent promoters (sigmulon) in Pseudomonas aeruginosa and implications for inflammatory processes in cystic fibrosis.

Authors:  Aaron M Firoved; J Cliff Boucher; Vojo Deretic
Journal:  J Bacteriol       Date:  2002-02       Impact factor: 3.490

Review 4.  Inhaled Antibiotics for Gram-Negative Respiratory Infections.

Authors:  Eric Wenzler; Dustin R Fraidenburg; Tonya Scardina; Larry H Danziger
Journal:  Clin Microbiol Rev       Date:  2016-07       Impact factor: 26.132

5.  Human polymorphonuclear leukocyte response to Pseudomonas aeruginosa grown in biofilms.

Authors:  E T Jensen; A Kharazmi; K Lam; J W Costerton; N Høiby
Journal:  Infect Immun       Date:  1990-07       Impact factor: 3.441

6.  Immunoglobulin A and immunoglobulin G antibody responses to alginates from Pseudomonas aeruginosa in patients with cystic fibrosis.

Authors:  S S Pedersen; F Espersen; N Høiby; T Jensen
Journal:  J Clin Microbiol       Date:  1990-04       Impact factor: 5.948

7.  Pseudomonas aeruginosa alginate in cystic fibrosis sputum and the inflammatory response.

Authors:  S S Pedersen; A Kharazmi; F Espersen; N Høiby
Journal:  Infect Immun       Date:  1990-10       Impact factor: 3.441

8.  Immunization with Pseudomonas aeruginosa vaccines and adjuvant can modulate the type of inflammatory response subsequent to infection.

Authors:  H K Johansen; F Espersen; S J Cryz; H P Hougen; A Fomsgaard; J Rygaard; N Høiby
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

Review 9.  Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia.

Authors:  J R Govan; V Deretic
Journal:  Microbiol Rev       Date:  1996-09

10.  In vitro and in vivo activity of EDTA and antibacterial agents against the biofilm of mucoid Pseudomonas aeruginosa.

Authors:  Zhenqiu Liu; Yaying Lin; Qi Lu; Fang Li; Jialin Yu; Zhengli Wang; Yu He; Chao Song
Journal:  Infection       Date:  2016-05-17       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.